Diagnostics

Mochida receives import approval for Osteomark NTx Serum test

Published in Blood Weekly, September 26th, 2002

Ostex International, Inc., (OSTX) announced its Japanese partner, Mochida Pharmaceutical Co., Ltd., has been granted import approval for the Osteomark NTx Serum test in Japan.

Ostex will now begin selling the Osteomark NTx Serum test, in the microtiter format, exclusively to Mochida for distribution in Japan.

Under the terms of the agreement with Mochida, the import approval from the Ministry of Health, Labor and Welfare (MHLW, formally Koseisho) triggers a $250,000 milestone payment from Mochida to Ostex.

Thomas Bologna, chairman, president, and CEO of Ostex stated, "Mochida has done an excellent job in establishing the NTx...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-09-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry